Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating an HLA-A*2402 restricted peptide vaccine for colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• HLA-A*2402 restricted peptide vaccine

Snippet

Sponsor: Tokyo University | Conditions: Colorectal Cancer, Colon Cancer | Phase 1, Phase 2 | Status: TERMINATED